Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chin Clin Oncol. 2021 Dec;10(6):56. doi: 10.21037/cco-21-82. Epub 2021 Nov 16.
To review and discuss the rationale behind performing baseline 18-fluorodeoxyglucose positron emission tomography-computed tomography imaging for staging of inflammatory breast cancer patients.
In the past three decades, the epidemiology of inflammatory breast cancer has resulted in separation of this entity from other breast cancer in staging and treatment. Advances in cancer imaging from 18-fluorodeoxyglucose positron emission tomography to 18-fluorodeoxyglucose positron emission tomography-computed tomography have now allowed for anatomic and functional correlation in evaluating extent of disease in cancer patients. Furthermore, studies throughout the past two decades have highlighted how 18-fluorodeoxyglucose positron emission tomography-computed tomography may play a role in staging inflammatory breast cancer patients given the uniqueness of this entity when compared to other breast cancers.
Narrative overview of the literature summarizing findings in the literature from searches in computerized databases and authoritative texts. The use of 18-fluorodeoxyglucose positron emission tomography-computed tomography with respect to regional nodal staging and distant metastasis detection in inflammatory breast cancer patients is reviewed. In addition, an overview of studies conducted to date comparing the sensitivity and specificity of 18-fluorodeoxyglucose positron emission tomography-computed tomography for baseline staging in inflammatory breast cancer patients is also provided. Therapeutic influences and effect on overall survival is discussed.
Baseline 18-fluorodeoxyglucose positron emission tomography-computed tomography allows for more optimal nodal staging, which has implications in prognosis and treatment of inflammatory breast cancer patients. It also allows for improved detection of metastasis on baseline presentation allowing therapy to potentially target these additional sites of disease.
回顾和讨论对炎性乳腺癌患者进行基线 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描成像分期的基本原理。
在过去的三十年中，炎性乳腺癌的流行病学导致了这种疾病在分期和治疗方面与其他乳腺癌的分离。从 18 氟-脱氧葡萄糖正电子发射断层扫描到 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描的癌症成像技术的进步，现在可以在评估癌症患者疾病程度时进行解剖学和功能相关性。此外，过去二十年的研究强调了 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描如何在分期炎性乳腺癌患者中发挥作用，因为与其他乳腺癌相比，这种实体具有独特性。
对文献进行计算机数据库和权威文本检索的文献综述，概述文献中的发现。回顾了 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描在炎性乳腺癌患者区域淋巴结分期和远处转移检测中的应用。此外，还概述了迄今为止比较 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描在炎性乳腺癌患者基线分期中的敏感性和特异性的研究。还讨论了治疗的影响和对总生存的影响。
基线 18 氟-脱氧葡萄糖正电子发射断层扫描-计算机断层扫描可实现更优化的淋巴结分期，这对炎性乳腺癌患者的预后和治疗具有重要意义。它还可以提高对基线表现的转移检测，从而使治疗有可能针对这些额外的疾病部位。
